CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) announced today that it will postpone the release of its financial results and the conference call for the fourth quarter and year-end 2010, both originally scheduled for February 22, 2011.
Kevin Green, vice president and chief accounting officer, said, "Due to the complexities of the accounting and audit processes associated with the Cerus’ acquisition of BioOne Corporation's assets, it has taken longer than expected to finalize our year-end financial statements. We will provide new dates and times for the earnings release and conference call in a forthcoming news release."
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Kevin D. Green
Vice President, Finance & CAO
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Infectious Diseases Medical Devices